Part of The Revenue Model Sets the Strategy
The Pharma Lens
The buyer whose revenue sits furthest from the platform.
01
Why pharma breaks the pattern
The five revenue models in this framework describe how a digital health company gets paid, and the payment structure sets the CS motion. The buyer sits on top of that structure rather than replacing it.
Who is doing the paying changes which stakeholders hold power, what counts as proof, and how the value story has to be told.
Pharmaceutical companies are a buyer that digital health CS teams routinely get wrong. The contracts are often large. The stakeholders are sophisticated. And the failure mode is almost always the same: a CS team that inherits a pharma account and tries to run it like a health plan account, because the contract looks similar on paper.
It doesn't work. Here's why.
02
How pharma buys digital health
Pharma companies are almost exclusively SaaS or Hybrid buyers. The most common structure is a platform license for a drug companion app or patient support tool, often combined with performance components tied to enrollment volume, adherence milestones, or real-world evidence generation. The contract may include a base fee for platform access plus milestone payments when defined patient thresholds are reached or data deliverables are submitted. How a platform license behaves once signed is the subject of SaaS Platform Licensing. How two payment streams in one contract pull CS in different directions is the subject of Hybrid Models.
Pharma rarely buys on a PMPM or CPT model because they aren't operating inside the healthcare reimbursement system the way payers and providers are. Their financial logic is different: they're investing in digital health to support their drug's commercial performance, their pipeline's evidence base, or both.
One pharma revenue stream sits outside this framework's scope entirely: media and advertising arrangements, where pharma pays digital health companies for audience reach rather than for a CS-managed program. That's an advertising business, not a customer success motion.
03
The stakeholder map
This is where pharma diverges from every other buyer in this framework. There is no clinic administrator tracking CPT codes. There is no HR benefits leader worried about employee absenteeism. The stakeholders are:
Medical affairs cares about the scientific integrity of the real-world evidence the program generates. They want study designs that will hold up to peer review, data collection that meets publication standards, and outcomes that support label expansion or pipeline development. They're often the internal champion who got the program funded, and they're measuring success in terms of data quality and publication potential, not engagement rates.
Commercial / brand teams care about whether the digital tool is supporting drug adoption and market positioning. Does the companion app improve patient experience enough to differentiate the drug from competitors? Are prescribers recommending the app at point of care? Is the patient support program reducing early discontinuation? Their success metrics are downstream from the drug's commercial performance, not the platform's engagement dashboard.
Market access cares about whether the digital program generates the kind of real-world evidence that supports payer coverage decisions, formulary placement, or outcomes-based drug contracts. This is a common use case: pharma companies deploy digital tools specifically to generate the real-world evidence health plans require before covering a high-cost therapy. CS needs to understand this strategic intent because it shapes which data matters and how it should be reported.
R&D / clinical development may be involved when the platform is part of a decentralized clinical trial, a post-market study, or a patient-reported outcomes collection effort. Their requirements are methodologically rigorous and timeline-driven in ways that operational stakeholders are not. A missed data collection window is not an inconvenience. It's a protocol deviation.
Patient support program leads own the hub services, copay assistance, and patient access programs that often sit alongside the digital tool. They care about enrollment rates (enrolled / patients offered the program), time-to-therapy, and patient persistence. They're typically the operational owner of the day-to-day program and the stakeholder most likely to be in regular contact with the CS team.
04
Value drivers
The value drivers in a pharma account trace back to the drug, not the platform. That reorientation is the one CS teams arriving from payer or provider accounts most often miss. The platform is a means to an end. The end is drug performance. In the terms of the value-orientation lens, a pharma buyer is generating revenue. What makes it different is distance. The program extends treatment duration, supports prescription volume, and reduces early discontinuation, and every one of those lands in drug sales rather than in a reimbursement claim or a medical loss ratio. Evidence generation sits further upstream on the same side, since real-world evidence secures the coverage that makes the revenue possible. Where the asset has no revenue yet, as in pipeline or label-expansion work, the same logic runs as de-risking rather than as growth. That distance is why platform-centric metrics land flat here and why the value story has to be told in the drug's terms.
That means value is measured through drug adherence rates among enrolled patients versus non-enrolled patients, real-world evidence generated and its publishability, prescriber engagement and advocacy, time-to-therapy for newly diagnosed patients, and early discontinuation rates (patients stopping therapy / patients started on it). A pharma buyer who sees strong platform engagement but weak adherence-to-drug data does not have a successful program. The engagement metrics are a leading indicator. The drug-related outcomes are the proof.
05
The activation challenge
The activation problem in pharma accounts is the hardest in this framework. The pharma company pays for the platform. The patients who need to use it are patients on their drug. The CS team has no direct relationship with those patients. The prescribers who could recommend the platform may or may not do so consistently. And the patient support program may be run by a third-party hub that the CS team doesn't manage.
This creates an activation chain with multiple handoffs and no single owner. The patient has to be diagnosed, prescribed the drug, connected to the patient support program, offered the digital tool, and choose to enroll. CS can influence some of those steps and has no visibility into others. Every patient-facing message in that chain also passes medical, legal, and regulatory review before it ships, which lengthens every activation cycle and rules out the fast iteration that works in payer and employer accounts.
The CS plays that matter most here are not traditional account management activities. Three of them carry the account.
Prescriber enablement. Prescribers have to know the tool exists and recommend it at the point of care.
Patient support program integration. The hub has to offer enrollment at the right touchpoints in the patient journey.
Activation funnel analytics. Tracking where patients drop out of the chain is what lets an intervention land at the stage that is actually leaking, which is the Engagement Gate's diagnostic applied to a chain with more handoffs.
06
CS and QBR implications
The QBR conversation in a pharma account does not look like a health plan QBR or an employer QBR. There is no HEDIS measure to report on. There is no cost savings calculation. The metrics that matter are enrollment volume by patient cohort, adherence rate among enrolled versus non-enrolled patients, real-world evidence data completeness and quality, prescriber recommendation rates where trackable (prescribers recommending / prescribers reached), and progress against any milestone payments tied to enrollment or data thresholds.
The executive sponsor relationship is typically in Medical Affairs or Commercial, not in a C-suite operations role. That means the language of the QBR is scientific and commercial, not operational. Slides that show feature utilization rates and NPS scores will land flat. Slides that show adherence lift, enrollment trajectory against milestone thresholds, and data quality metrics for the real-world evidence study will land.
One structural challenge worth naming: pharma accounts have a long gap between program launch and meaningful outcome data. Drug adherence studies take 6 to 12 months to produce interpretable signals. Real-world evidence studies may run 18 to 24 months before submission. CS must build an interim reporting cadence that keeps stakeholders engaged and confident during the data collection period, because the window where a program feels like it isn't producing results is the window where internal champions lose organizational support. Quarterly updates on enrollment trends, data completeness, and early proxy signals are how CS protects the contract until the proof arrives.
07
Where to go next
The five model pages cover how each model gets paid, how the buyer's payment environment shifts the value story, and an example drawn from practice. Four of them also map the stakeholder value drivers, and the hybrid page maps contract structures instead. Pharma buys on two of those structures, SaaS Platform Licensing and Hybrid Models, so those two pages are where a pharma contract's mechanics live. The Engagement Gate page carries the threshold every model has to cross before its value story starts, along with the lag comparison across all five models and the rules for reporting an engagement rate honestly, which the activation funnel on this page has to follow.
The other two buyer lenses come at it the same way this page does, by who is doing the paying. Health plans are the most structurally complex buyer, where quality measure improvement and total cost of care reduction drive the value story and the definition of success can shift mid-contract. Employers are the buyer whose day-to-day contact rarely controls the budget, so CS's real deliverable is the internal case the HR leader carries to the person who does.
Take the working structures with you
The Field Kit pulls the framework's durable layer out into structures built for use rather than reading: the identify-your-model diagnostic, blank stakeholder and KPI worksheets, the tiered QBR builder, the hybrid trade-off script, the believable-proof checklist, and the seven-step guide to putting the framework to work on a live account. Version-stamped, designed to print, and free to subscribers, who get it first when it ships. Billing-code specifics stay on this site by design, so the kit stays accurate as the rules change.
Your email delivers the kit when it ships, plus occasional new insights from Digital Health Success. No spam. Unsubscribe anytime.